93 related articles for article (PubMed ID: 14645441)
1. Importance of minimal residual disease testing during the second year of disease: still no answer?
Aricò M; Conter V; Valsecchi MG; Masera G
J Clin Oncol; 2003 Dec; 21(23):4463-4; author reply 4464-5. PubMed ID: 14645441
[No Abstract] [Full Text] [Related]
2. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
[No Abstract] [Full Text] [Related]
3. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications.
Roberts WM; Zipf TF; Kitchingman GR; Tubergen DG; Estrov Z
Cytokines Mol Ther; 1995 Mar; 1(1):65-9. PubMed ID: 9384665
[TBL] [Abstract][Full Text] [Related]
4. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.
Marshall GM; Haber M; Kwan E; Zhu L; Ferrara D; Xue C; Brisco MJ; Sykes PJ; Morley A; Webster B; Dalla Pozza L; Waters K; Norris MD
J Clin Oncol; 2003 Feb; 21(4):704-9. PubMed ID: 12586809
[TBL] [Abstract][Full Text] [Related]
5. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
6. Quantifying leukemia.
Morley A
N Engl J Med; 1998 Aug; 339(9):627-9. PubMed ID: 9718385
[No Abstract] [Full Text] [Related]
7. Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.
Advani AS
Clin Adv Hematol Oncol; 2011 Oct; 9(10):776-7. PubMed ID: 22252580
[No Abstract] [Full Text] [Related]
8. The U.S. trials in adult acute lymphoblastic leukemia.
Larson RA
Ann Hematol; 2004; 83 Suppl 1():S127-8. PubMed ID: 15124704
[No Abstract] [Full Text] [Related]
9. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation.
Goulden N; Oakhill A; Steward C
Br J Haematol; 2001 Feb; 112(2):275-81. PubMed ID: 11167819
[No Abstract] [Full Text] [Related]
10. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
12. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual disease in childhood acute lymphoblastic leukemia.
Faderl S; Estrov Z
N Engl J Med; 1999 Jan; 340(2):152-3; author reply 153-4. PubMed ID: 9917220
[No Abstract] [Full Text] [Related]
16. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
18. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
Schüler F; Dölken G
Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
[TBL] [Abstract][Full Text] [Related]
19. Use of simplified strategies to evaluate early treatment response in childhood acute lymphoblastic leukemia.
Scrideli CA; de Paula Queiróz R; Bernardes JE; Defavery R; Valera ET; Tone LG
Leuk Res; 2006 Aug; 30(8):1049-52. PubMed ID: 16406015
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
